Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30698940 | 0.82 | POLB (0.42) | MAPTHCAR3MAPK1LMNAALDH1A1 | |
| SCHEMBL1585679 | 0.82 | POLB (0.42) | MAPTHCAR3MAPK1LMNAALDH1A1 | |
| SCHEMBL3449492 | 0.82 | HCAR3 (0.46) | MAPTHCAR3L3MBTL1MAPK1LMNA | |
| SCHEMBL23235710 | 0.81 | LMNA (0.65) | MAPTHCAR3L3MBTL1LMNAALDH1A1 | |
| SCHEMBL30676115 | 0.81 | LMNA (0.65) | MAPTHCAR3L3MBTL1LMNAALDH1A1 | |
| SCHEMBL3449318 | 0.81 | PGK1 (0.48) | MAPTHCAR3L3MBTL1MAPK1LMNA | |
| SCHEMBL15740537 | 0.81 | KMT2A (0.40) | MAPTL3MBTL1MAPK1LMNAALDH1A1 | |
| SCHEMBL15749046 | 0.80 | HCAR3 (0.50) | MAPTHCAR3L3MBTL1ALDH1A1GAA | |
| SCHEMBL19013400 | 0.80 | HCAR3 (0.50) | MAPTHCAR3L3MBTL1ALDH1A1GAA | |
| SCHEMBL15749103 | 0.80 | HCAR3 (0.50) | MAPTHCAR3L3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | MAPT 3969/4885HCAR3 3646/4885L3MBTL1 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.